Search Result

Results for "

lymphoma cancers,

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (2) BCL6 (1) MALT1 (1) ADC Antibody (1) ADC Payload (5) Akt (2) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (7) Antifolate (1) Apoptosis (32) Autophagy (8) Bacterial (5) Bcl-2 Family (8) Btk (4) c-Fms (1) c-Myc (5) C-type Lectin-like Receptors (CTLRs) (2) Caspase (2) CCR (2) CD19 (2) CD20 (4) CD22 (2) CD28 (1) CD47 (1) CDK (4) COX (1) CRM1 (1) CXCR (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (7) E1/E2/E3 Enzyme (2) EGFR (1) Epigenetic Reader Domain (1) ERK (2) Fc Receptor (FcR) (1) Fluorescent Dye (1) Fungal (5) HDAC (3) Histone Methyltransferase (3) IKZF Family (1) Influenza Virus (1) Integrin (2) Isotope-Labeled Compounds (5) Lactate Dehydrogenase (1) Ligands for E3 Ligase (1) Liposome (2) MAP4K (1) MDM-2/p53 (4) MHC (1) Microtubule/Tubulin (4) Mitosis (1) MMP (3) Molecular Glues (3) mRNA (2) N-myristoyltransferase (2) NF-κB (1) Parasite (4) PD-1/PD-L1 (6) Phospholipase (1) PI3K (5) PROTACs (3) PTEN (2) Radionuclide-Drug Conjugates (RDCs) (2) Ras (2) Reactive Oxygen Species (ROS) (2) Reference Standards (4) SARS-CoV (2) SHMT (1) STAT (1) Survivin (1) Tim3 (1) TNF Receptor (5) Topoisomerase (5) Transferrin Receptor (1) Transmembrane Glycoprotein (2) Tyrosinase (2) Wnt (1)
By Research Areas:	Cancer (112) Cardiovascular Disease (6) Endocrinology (1) Infection (13) Inflammation/Immunology (22) Metabolic Disease (3) Neurological Disease (6)
Oligonucleotides:	Pegylated Lipids (1) Nucleotide Analogs (1) mRNA (2) Uracil Nucleotide (1)

113

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

Vincristine 60+ Cited Publications Leurocristine; NSC-67574; 22-Oxovincaleukoblastine	Microtubule/Tubulin Antibiotic Mitosis	Cancer
Vincristine (Leurocristine) is a microtubule-destabilizing agent (MDA). Vincristine binds to tubulin and inhibits the formation of microtubules, thereby inhibiting mitosis of the cancer cell. Vincristine is used to research hematologic cancers, such as leukemia and lymphoma, and childhood sarcomas .

Scriptaid 4 Publications Verification Scriptide; GCK1026	HDAC Autophagy Apoptosis Influenza Virus	Cancer
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.

Asaretoclax	Bcl-2 Family	Cancer
Asaretoclax is a potent *B-cell lymphoma* 2 (Bcl-2)** inhibitor. Asaretoclax has the potential for the research of cancer .

GL-331	Apoptosis	Cancer
GL-331 is a potent anti-cancer agent. GL-331 has demonstrated more efficacious anti-cancer activity in both the in vitro and in vivo lymphoma systems .

Tubulin polymerization-IN-32	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-32 is a tubulin polymerization inhibitor. Tubulin polymerization-IN-32 inhibits cancer cell proliferation. Tubulin polymerization-IN-32 can be used in the research of cancers like lymphomas .

Bleomycin	Antibiotic	Cancer
Bleomycin is a glycopeptide antibiotic. Bleomycin has potent antitumour activities against a range of lymphomas, head and neck cancers and germ-cell tumours. Bleomycin can be used for the research of cancer and chemotherapy .

(Rac)-Antineoplaston A10	Ras Apoptosis	Cancer
(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer .

Porcn-IN-2	Wnt	Cancer
Porcn-IN-2 (Example 107) is a Wnt inhibitor, with an IC₅₀ value of 0.05 nM. Porcn-IN-2 can be used for research of cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia, etc .

TJ191	Apoptosis	Cancer
TJ191 is a potent and specific *anti-cancer* agent** that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research .

ZM-008	C-type Lectin-like Receptors (CTLRs)	Cancer
ZM-008 is a human monoclonal antibody (mAb) targeting OCIL/CLEC2D. ZM-008 can be used in B-cell lymphoma, glioma and prostate cancer research.

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

LP-284	DNA Alkylator/Crosslinker	Cancer
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .

Edatrexate CGP 30694	Antifolate	Cancer
Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .

SGN-30	Apoptosis	Cancer
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .

BCL6-IN-9	Bcl-2 Family	Cancer
BCL6-IN-9 (compound 1) is a potent *B-cell lymphoma* 6 protein (BCL6) inhibitor, with an IC₅₀** of 3.9 nM. BCL6-IN-9 can be used for the research of cancer .

Dencatistat	DNA/RNA Synthesis	Inflammation/Immunology Cancer
Dencatistat (P115) is an inhibitor of Cytidine Triphosphate Synthase 1 (CTPS1) with an IC₅₀ value of ≤ 0.1 μM. Dencatistat can be used for research on cancer (such as leukemia and lymphoma), inflammatory skin diseases (such as psoriasis), or multiple sclerosis .

LFS-1107	CRM1 COX c-Myc Survivin	Cancer
LFS-1107 is a reversible CRM1 inhibitor (K_d: 12.5 pM). LFS-1107 can selectively eliminate extranodal natural killer/T cell lymphoma (ENKTL) cells and can be used for cancer research .

Tifcemalimab JS004; Icatolimab	CD28	Cancer
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer, such as lymphoma and non-small cell lung cancer (NSCLC) .

Tositumomab Anti-Human CD20 Recombinant Antibody; V10XA53	CD20	Cancer
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .

Imofinostat ABT-301; MPT0E028; TMU-C-0012	HDAC Akt Apoptosis	Inflammation/Immunology Cancer
Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC₅₀s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC₅₀ of 2.5 μM), but no inhibitory effect on HDAC4 (IC₅₀>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .

PQ32	c-Myc Ras Apoptosis	Cancer
PQ32 is an antitumor agent that targets c-MYC Pu27 and KRAS G-quadruplexes. PQ32 inhibits tumor cell proliferation, arrests the cell cycle at the G2 phase, and induces apoptosis. PQ32 inhibits the expression of c-MYC and KRAS genes. PQ32 can inhibit tumor growth in mice and is used in the study of lymphoma, breast cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, and other cancers .

Aderbasib INCB007839; INCB7839	MMP	Cancer
Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 ⁺ breast cancer, gliomas, et al .

5-Feruloylquinic acid	Tyrosinase	Cancer
5-Feruloylquinic acid (5-FQA) is a hydroxycinnamic acid derivative. 5-Feruloylquinic acid can be isolated from green coffee beans. 5-Feruloylquinic acid inhibits tyrosinase activity. 5-Feruloylquinic acid has antioxidant properties. 5-Feruloylquinic acid has anticancer activity against lymphoma, oral epidermal cancer, and breast cancer .

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

Tubulin polymerization-IN-37	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-37 is a tubulin polymerization inhibitor (IC₅₀: 2.3 μΜ). Tubulin polymerization-IN-37 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-37 can be used in the research of cancers, such as lymphomas .

Tubulin polymerization-IN-36	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-36 is a tubulin polymerization inhibitor (IC₅₀: 2.8 μΜ). Tubulin polymerization-IN-36 binds to the colchicine site of tubulin and inhibits colchicine binding. Tubulin polymerization-IN-36 can be used in the research of cancers, such as lymphomas .

BTK-IN-27	Btk	Inflammation/Immunology Cancer
BTK-IN-27 (example 8) is a BTK inhibitor (IC₅₀: 0.2 nM). BTK-IN-27 shows anti-proliferative activity in TMD8 cells (IC₅₀: < 5 nM). BTK-IN-27 can be used for research of cancer, lymphoma, leukemia and immunological diseases .

F6524-1593	Anaplastic lymphoma kinase (ALK)	Cancer
F6524-1593 is an ALK inhibitor. F6524-1593 has inhibitory activity against A549 and HepG-2 cells with IC₅₀ values of 161.1 μM and 91.03 μM, respectively. F6524-1593 can be used in the research of ALK-related cancers (such as non-small cell lung cancer, lymphoma and neuroblastoma) .

Daunorubicin Daunomycin; RP 13057; Rubidomycin	Topoisomerase DNA/RNA Synthesis ADC Payload Autophagy Bacterial Antibiotic Apoptosis	Infection Neurological Disease Cancer
Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .

Daunorubicin hydrochloride 30+ Cited Publications Daunomycin hydrochloride; RP 13057 hydrochloride; Rubidomycin hydrochloride	Topoisomerase DNA/RNA Synthesis ADC Payload Bacterial Autophagy Apoptosis Antibiotic	Infection Neurological Disease Cancer
Daunorubicin (Daunomycin) hydrochloride is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin hydrochloride inhibits DNA and RNA synthesis. Daunorubicin hydrochloride is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin hydrochloride is also an anthracycline antibiotic. Daunorubicin hydrochloride can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .

(S)-Sabutoclax (S)-BI-97C1	Bcl-2 Family	Cancer
(S)-Sabutoclax ((S)-BI-97C1), an optically pure apogossypol derivative, is pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. (S)-Sabutoclax (Compound II) inhibits the binding of BH3 peptides to Bcl-XL, Bcl-2, Mcl-1, and Bfl-1 with IC₅₀ values of 0.31, 0.32, 0.20, and 0.62 μM, respectively. (S)-Sabutoclax also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC₅₀ values of 0.13, 0.56, and 0.049 μM, respectively. (S)-Sabutoclax can be used for the research of apoptosis-based therapies against cancer .

Veltuzumab IMMU-106; hA20	Integrin	Cancer
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC₅₀ value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .

Antitumor agent-23	Others	Cancer
Antitumor agent-23 is a potent anti-cancer agent with GI₅₀s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity .

SHMT-IN-2	SHMT	Endocrinology Cancer
SHMT-IN-2 is a stereo specific inhibitor of human SHMT1/2 with IC₅₀ values of 13 nM and 66 nM for SHMT1 and SHMT2, respectively. SHMT-IN-2 can block the growth of many human cancer cells, and has sensitivity for B-cell lymphomas .

Carbendazim hydrochloride	Fungal Parasite	Infection Cancer
Carbendazim hydrochloride is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim hydrochloride is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .

Carbendazim 5 Publications Verification	Fungal Parasite	Infection Cancer
Carbendazim is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .

NOTA	Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

EtDO-P4	ERK	Cancer
EtDO-P4 is a nanomolar inhibitor of glycosphingolipid (GSL) synthesis. EtDO-P4 suppresses activation of the EGFR-induced ERK pathway and various receptor tyrosine kinases (RTKs). EtDO-P4 can be used for various types of cancer, including Burkitt’s lymphoma .

JS25	Btk	Cancer
JS25 is a selective and covalent inhibitor of BTK that inactivates BTK with an IC₅₀ value of 5.8 nM by chelating Tyr551. JS25 inhibits cancer cells proliferation, pronounces cell death, and promotes murine xenograft model of Burkitt’s lymphoma. JS25 effectively crosses the blood-brain barrier .

MMRi64	MDM-2/p53 Apoptosis	Cancer
MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research .

FX-11 20+ Cited Publications LDHA Inhibitor FX11	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS)	Cancer
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .

Sym023	Tim3	Cancer
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .

Daunorubicin citrate Daunomycin(citrate); RP 13057(citrate); Rubidomycin(citrate)	Topoisomerase DNA/RNA Synthesis ADC Payload Autophagy Bacterial Antibiotic Apoptosis	Infection Neurological Disease Cancer
Daunorubicin (Daunomycin) citrate is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin citrate inhibits DNA and RNA synthesis. Daunorubicin citrate is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin citrate is also an anthracycline antibiotic. Daunorubicin citrate can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .

CDK-TCIP2	CDK BCL6	Cancer
DK-TCIP2, linking inhibitor of CDK9 SNS-032 (HY-10008) with ligands of BCL6 BI-3812 (HY-111381), is a anticancer agent. DK-TCIP2 shows anticancer activity in vivo and in vitro and can be used for study of lymphoma cancer .

Cat. No.	Product Name

HY-L079

Anti-Blood Cancer Compound Library

3,626 compounds

Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.

Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.

MCE offers a unique collection of 3,626 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

HY-L075

Anti-Lung Cancer Compound Library

2,494 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 2,494 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Type

HY-140739

DSPE-PEG2000-Maleimide

2 Publications Verification

Drug Delivery

DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .

Cat. No.	Product Name	Target	Research Area

HY-172320

BMS-986238	PD-1/PD-L1	Cancer
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .

Cat. No.	Product Name	Target	Research Area

HY-P99501

Zuberitamab HS006	CD20	Cancer
Zuberitamab (HS006) is a monoclonal antibody that targets CD20 and can be used in cancer research, including diffuse large B-cell lymphoma .

HY-P99253

Mogamulizumab KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99961

Tifcemalimab JS004; Icatolimab	CD28	Cancer
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer, such as lymphoma and non-small cell lung cancer (NSCLC) .

HY-P99326

Tositumomab Anti-Human CD20 Recombinant Antibody; V10XA53	CD20	Cancer
Tositumomab (Anti-Human CD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to human CD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .

HY-P99224

Veltuzumab IMMU-106; hA20	Integrin	Cancer
Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC₅₀ value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .

HY-P99851

Detumomab SPECIFID	Inhibitory Antibodies	Cancer
Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).

HY-P991309

ZM-008	C-type Lectin-like Receptors (CTLRs)	Cancer
ZM-008 is a human monoclonal antibody (mAb) targeting OCIL/CLEC2D. ZM-008 can be used in B-cell lymphoma, glioma and prostate cancer research.

HY-P991512

SGN-30	Apoptosis	Cancer
SGN-30 is a chimeric antibody derived from a mouse antihuman CD30 antibody, AC10, with the variable regions of AC10 and human α 1 heavy chain and κ light chain constant regions. SGN-30 induces apoptosis and cell-cycle arrest in cancer cells. SGN-30 can be used for the study of Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991397

Sym023	Tim3	Cancer
Sym023 is a human monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. Sym023 enhances immunostimulatory and anti-tumor activities. Sym023 can be used in Non-small cell lung cancer, Solid tumors and Lymphoma research .

HY-P991550

RFB4	CD22	Cancer
RFB4 is a anti-CD22 monoclonal antibody. RFB4 can construct recombinant immunotoxins by fusing with copper green pseudomonas exotoxin (PE38) through disulfide bonds such as RFB4(dsFv)-PE38. RFB4 can be used for research on cancer such as lymphoma .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99230

Pinatuzumab	Integrin CD22	Cancer
Pinatuzumab is a humanized monoclonal antibody targeting cell-surface antigen CD22. Pinatuzumab can be used to synthesize antibody-drug conjugate (ADC) such as Pinatuzumab vedotin (HY-141602). Pinatuzumab can be studied in research on cancer such as non-Hodgkin lymphoma. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99151

Brentuximab	ADC Antibody TNF Receptor	Cancer
Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC₅₀ of 10 nM against human CD30+ cancer cells .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99119

Anti-Mouse 4-1BB/CD137 Antibody (3H3)	TNF Receptor Bcl-2 Family	Inflammation/Immunology Cancer
Anti-Mouse 4-1BB/CD137 Antibody (3H3) is an anti-mouse 4-1BB/CD137 IgG2a monoclonal antibody. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can effectively activate memory T cells and inhibit tumors by increasing Bcl-xL and granzyme B levels. Anti-Mouse 4-1BB/CD137 Antibody (3H3) can be used for research on cancer such as lymphoma and colon cancer .

HY-P991555

XmAb5485	TNF Receptor Apoptosis	Cancer
XmAb5485 is an Fc-engineered humanized anti-CD40 monoclonal antibody with high affinity to Fc-γ receptors. XmAb5485 induces potent antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) against tumor cells. XmAb5485 inhibits proliferation and induces apoptosis of tumor cells. XmAb5485 shows highly cytotoxic against lymphoma, leukemia and multiple myeloma cell lines as well as primary cancer cells .

HY-P990856

Anti-CD71 Antibody (OKT-9)	Transferrin Receptor	Cancer
Anti-CD71 Antibody (OKT-9) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD71. Anti-CD71 Antibody (OKT-9) can recognize CD71 also known as Transferrin receptor protein 1 (TfR1). Anti-CD71 Antibody (OKT-9) can be used for the detections of immunohistochemistry, immunofluorescence and flow cytometry in cancer, such as leukemia and lymphoma .

HY-P991553

HeFi-1	TNF Receptor Apoptosis	Inflammation/Immunology Cancer
HeFi-1 is a mouse anti-CD30 IgG1 monoclonal antibody. HeFi-1 recognizes the ligand-binding site on CD30. HeFi-1 can inhibit the growth of tumor cells with high expression of CD30. HeFi-1 can induce eosinophil apoptosis. HeFi-1 can be used for researches on cancer or inflammation conditions such as anaplastic large-cell lymphoma (ALCL) and asthma .

HY-P990806

Anti-Mouse CD20 Antibody (MB20-11)	CD20	Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse CD20 Antibody (MB20-11) is a kind of mouse IgG2c antibody inhibitor, targeting to CD20. Anti-Mouse CD20 Antibody (MB20-11) can deplete mature B cells in lymphoid tissues. Anti-Mouse CD20 Antibody (MB20-11) can be used for the researches of cancer, immunology and metabolic Disease, such as lymphoma and diabetes .

HY-P991567

VX5 VX5/5261	CXCR	Inflammation/Immunology Cancer
VX5 is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration (EC₅₀s for 105 and 253 nM for human tonsillar and pre-B-697-hCXCR5 cells, respectively). VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .

HY-P991510

CDX-1140	TNF Receptor	Cancer
CDX-1140 is a human IgG2 CD40 agonist antibody. CDX-1140 activates dendritic cells (DCs) and B cells and drives NF-kB stimulation in a CD40-expressing reporter cell line. CDX-1140 is independent of FcR binding and synergistic with native CD40L signaling. CDX-1140 has both direct and immune-mediated anti-tumor activity. CDX-1140 can be used for the study of lymphoma cancer and solid tumors .

HY-P99052

Tislelizumab 3 Publications Verification BGB-A317	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the CD47-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-P991225

BI-1206	Fc Receptor (FcR) CD20	Inflammation/Immunology Cancer
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .

HY-P990180

Anti-Mouse NKG2A/C/E Antibody (20D5)	C-type Lectin-like Receptors (CTLRs)	Inflammation/Immunology Cancer
Anti-Mouse NKG2A/C/E Antibody (20D5) is an anti-mouse NKG2A/C/E IgG2a monoclonal antibody. Anti-Mouse NKG2A/C/E Antibody (20D5) can activate natural killer (NK) and CD8 ⁺ T cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can exacerbate liver pathological damage by enhancing the activation of iNKT cells. Anti-Mouse NKG2A/C/E Antibody (20D5) can be used for researches on cancer and immunology such as lymphoma .

HY-P990189

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243)	MHC Apoptosis Reactive Oxygen Species (ROS)	Infection Cancer
Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to monkey/human MHC class II. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can inhibits tumor cells proliferation and induce apoptosis. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) increases cellular reactive oxygen species (ROS) and loss of mitochondrial membrane potential in human endothelial cells. Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) can be used for the researches of cancer and infection, such as lymphoma .

HY-P990296

Anti-Mouse CCR3/CD193 Antibody (6S2-19-4)	CCR	Infection Inflammation/Immunology Cancer
Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) is a rat-derived IgG2b λ type antibody inhibitor, targeting to mouse CCR3/CD193. Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) can deplete eosinophils. Anti-Mouse CCR3/CD193 Antibody (6S2-19-4) can be used for the researches of cancer, infection, inflammation and immunology, such as lymphoma, ileitis and strongyloides stercoralis infection .

HY-P990855

Anti-CD8α Antibody (OKT-8)	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 ⁺ T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .

Cat. No.	Product Name	Chemical Structure

HY-W654130

Daunorubicin-13C,d3

Daunorubicin- ¹³C,d₃ is ¹³C and deuterium labeled Daunorubicin. Daunorubicin (Daunomycin) is a topoisomerase II inhibitor with potent anti-tumor activity. Daunorubicin inhibits DNA and RNA synthesis. Daunorubicin is a cytotoxin that inhibits cancer cell viability and induces apoptosis and necrosis. Daunorubicin is also an anthracycline antibiotic. Daunorubicin can be used in the research of infection and variety of cancers, including leukemia, non-Hodgkin lymphomas, Ewing's sarcoma, Wilms' tumor .

HY-13582S

Carbendazim-d4
Carbendazim-d₄ is the deuterium labeled Carbendazim. Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .

HY-W703549

Aderbasib-d3
Aderbasib-d₃ (INCB007839-d₃) is deuterium labeled Aderbasib. Aderbasib (INCB007839) is a potent, orally active and target specific low nanomolar hydroxamate-based inhibitor of ADAM10 and ADAM17. Aderbasib exhibits robust antineoplastic activity and can be used for cancer research, including diffuse large B-cell non-Hodgkin lymphoma, HER2 ⁺?breast cancer, gliomas, et al .

HY-13582S1

Carbendazimb-d3

Carbendazimb-d₃ is the deuterium labeled Carbendazimb (HY-13582). Carbendazim is a potent and orally active broad-spectrum?benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria,?Fusarium?and?Sclerotina . Carbendazim is a benzimidazole (HY-Y1825) derivative with antitumor activity and used for cancer research, especially advanced solid tumors and lymphoma .

HY-W013724S

Inosine-5'-diphosphate-15N4 dilithium

Inosine-5'-diphosphate- ¹⁵N₄ dilithium (IDP- ¹⁵N₄ dilithium) is ¹⁵N labeled Inosine-5'-diphosphate dilithium. Inosine-5'-diphosphate (IDP) is a decoy substrate of NM23-H2. Inosine-5'-diphosphate has a superior bond capacity on GDP-binding pocket of NM23-H2 (K_D: 5.0 μM). Inosine-5'-diphosphate abrogates c-MYC transcription, induces apoptosis and G2/M cell cycle arrest by disrupting NM23-H2-Pu27-GQ interactions without affecting NM23-H2-mediated kinase properties. Inosine-5'-diphosphate has antihypoxic, antihyperthermic and antiarrhythmic activity and protects animals against the noxious effects of γ-irradiation. Inosine-5'-diphosphate can be used for cancers like Burkitt's lymphoma and cardiovascular diseases research .

Cat. No.	Product Name		Classification

HY-W784565

5-Fluorouridine 5'-phosphate		Nucleotide Analogs Uracil Nucleotide
5-Fluorouridine 5'-phosphate is an ODCase (orotidine-5′-monophosphate decarboxylase) inhibitor, with a K_i value of 98 µM for human ODCase and a K_i value of 645 µM for Methanobacterium ODCase. 5-Fluorouridine 5'-phosphate exhibits inhibitory activity against leukemia and lymphoma cell lines and can be used in cancer research .

HY-140739

DSPE-PEG2000-Maleimide 2 Publications Verification		Pegylated Lipids
DSPE-PEG2000-Maleimide is a phospholipid-PEG conjugate. DSPE-PEG2000-Maleimide utilizes the amphiphilicity of DSPE to insert into the lipid bilayer of liposomes or nanoparticles. DSPE-PEG2000-Maleimide covalently couples to the sulfhydryl (-SH) of ligands (such as antibodies, peptides, or proteins) via thiol-maleimide click chemistry, giving the particles targeting capabilities. DSPE-PEG2000-Maleimide can be used in the researches of breast cancer, lymphoma, and inherited retinal degeneration .

HY-153084

CD19 CAR mRNA (Mouse)		mRNA
CD19 CAR mRNA (Mouse) is an mRNA designed based on FMC63-28Z. FMC63–28Z had a scFv from a murine antibody (FMC63, a recombinant monoclonal antibody specific for human CD19), hinge, transmembrane, and cytoplasmic domains from CD28, and a CD3ζ domain. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

HY-153084A

CD19 CAR mRNA (Human)		mRNA
CD19 CAR mRNA (Human) expresses Human CD19 CAR protein. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks